More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$353.44B
EPS
0.97
P/E ratio
116.4
Price to sales
5.4
Dividend yield
2.371%
Beta
0.13111
Previous close
$144.46
Today's open
$143.32
Day's range
$142.31 - $144.89
52 week range
$92.11 - $156.92
show more
CEO
Robert M. Davis
Employees
75000
Headquarters
Rahway, NJ
Exchange
New York Stock Exchange
Shares outstanding
2.47B
Issue type
Common Stock
Healthcare
Pharmaceuticals
Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
RAHWAY, N.J.--(BUSINESS WIRE)--Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director.
Business Wire • 11 hours ago

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
Zacks Investment Research • 6 hours ago

Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.
Zacks Investment Research • 2 hours ago

Merck stops trials of blood cancer drug after risk assessment
Merck said on Tuesday it would stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the treatment's benefits may not outweigh the risks.
Reuters • Nov 17, 2026

Merck Announces First-Quarter 2027 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2027 Dividend.
Business Wire • Nov 17, 2026

Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other hematologic malignancies in the BELLWAVE program. Merck is discontinuing the.
Business Wire • Nov 17, 2026

Is Merck's Stock Still a Good Buy at $150?
Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on Keytruda are expiring in the near future.
The Motley Fool • Nov 16, 2026

Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug
Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab.
Investors Business Daily • Nov 16, 2026

Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November
I expect Nike (NKE) to raise its dividend 1.2–2.4%, as weak sales, flat EPS and a payout ratio around 80% constrain growth. Matthews International (MATW) risks a dividend cut; Hormel (HRL) faces an above-100% payout ratio and likely will increase its annual dividend just one cent. Motorola Solutions (MSI) should deliver a 10%+ increase, while Marzetti (MZTI) is poised to extend its 63-year streak with a roughly 5% boost.
Seeking Alpha • Nov 16, 2026

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck's first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult p.
Business Wire • Nov 13, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Merck & Company Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.